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Introduction: Diffuse aortoiliac occlusive disease or isolated external iliac artery occlusion >10 cm long typically are
treated with surgical bypass grafting because of limited durability of stent placement. We evaluated the results of
stent-graft placement as an option for treatment of these diseases.
Methods: Demographic data for patients undergoing stent-grafting in one or more iliac artery segments were recorded.
Technical, clinical, and hemodynamic success, and aortoiliac primary and secondary patency were analyzed with Society
for Vascular Surgery/American Association for Vascular Surgery criteria.
Results: Thirty-four consecutive patients underwent stent-graft treatment because of rest pain (65%) or tissue loss (35%).
Mean patient age was 63 years, and 38% of patients were women. Ninety-one percent of patients had hypertension, 71%
had coronary artery disease, 21% had renal insufficiency (serum creatinine > 2.0 mg/dL), and 26% had diabetes; 71% were
active smokers. TransAtlantic Inter-Society Consensus C or D disease was present in 85% of patients, complete common
or external iliac artery occlusion was present in 41%, and external iliac artery disease requiring treatment was present in
94% of patients. Mean lesion length was 13.7  8 cm. Technical, hemodynamic, and clinical success was achieved in all
patients in whom the lesion could be crossed with a wire. Ankle-brachial index increased from .30  .03 to .59  .04.
Self-expanding stent grafts were used (Wallgraft, Boston Scientific, Boston, Mass, in 88% of patients; Viabahn, W. L.
Gore, Flagstaff, Ariz, in 12% of patients). Concomitant common femoral endarterectomy was performed in 53% of
patients. At 12 months, primary patency was 70% and primary assisted patency was 88%. Four stent grafts became
occluded because of distal external iliac artery or proximal common femoral artery disease, which required subsequent
common femoral endarterectomy and either external iliac artery stent grafting or extraanatomic bypass grafting. Eighty
percent (four of five) of primary patency failures were in patients who did not undergo concomitant common femoral
endarterectomy at initial stent graft placement.
Conclusion: Early results of stent-graft placement to treat diffuse aortoiliac occlusive disease appear better than our recent
experience with stenting alone. Concomitant common femoral endarterectomy or better assessment of femoral disease
may improve durability. (J Vasc Surg 2003;37:1175-80.)
Percutaneous angioplasty with selective stent place-
ment is effective in treating isolated focal iliac stenosis or
occlusion. Four-year primary patency rate of 50% to 80%
can be expected after angioplasty with selective stent place-
ment, depending on lesion length, location, and severi-
ty.1-6 On the other hand, results with iliac stents for treat-
ment of diffuse or multisegment iliac occlusive disease have
not been promising. This is especially true when diffuse
occlusive lesions involve the external iliac arteries.7 We have
previously shown that in a subgroup of patients with diffuse
iliac occlusive disease also involving the external iliac arter-
ies the primary and secondary patency rates after stent
treatment were only 30% and 53%, respectively, at 12
months.8 Of more concern is that as the complexity of
percutaneous revascularization increases so does the com-
plication rate. In our series of iliac stents used to treat
multisegment iliac occlusive disease, the serious complica-
tion rate was 11%, considerably higher than the 1% to 3%
complication rate observed after percutaneous treatment of
isolated iliac lesions.7 Several series with a limited number
of patients have demonstrated that stent-graft treatment of
diffuse iliac occlusive disease may be a useful alternative to
aortobifemoral or axillofemoral bypass grafting. Marin et
al,9 using a homemade stent graft, found 81% patency at 24
months after stent-graft treatment.
Aortobifemoral bypass remains the standard for treat-
ment of diffuse iliac occlusive disease. A recent TransAtlan-
tic Inter-Society Consensus (TASC) document on treat-
ment of peripheral vascular disease stated that TASC C and
D iliac disease (Fig 1), which by definition involves multiple
iliac segments, is best treated with open revascularization.10
Bypass surgery has demonstrated the best long-term dura-
bility, with 5-year patency in excess of 80%, but is associated
with a perioperative complication rate of up to 30%.11-17 In
addition, aortobifemoral bypass grafting results in 2 or
more months of absence from work, which many young
patients cannot tolerate financially. Thus the need for a
durable, safe, and less invasive approach to treatment of
diffuse iliac disease remains.
The purpose of the present study is to report our early
experience with stent-graft treatment of multisegment dif-
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fuse iliac occlusive disease. Specifically, early patency and
complication rate of stent-graft treatment of diffuse iliac
disease is compared with our previously reported experi-
ence of angioplasty with selective stent placement in a
similar group of patients
METHODS
Between January 2001 and September 2002, 34 pa-
tients underwent iliac artery stent grafting of diffuse iliac
artery occlusive disease. Diffuse iliac artery occlusive disease
Fig 1. Preferred options for interventional management of iliac lesions.
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was defined in this study as occlusion of bilateral common
iliac arteries, some combination of common and external
iliac arteries, or bilateral external iliac arteries, or complete
occlusion or stenosis of one iliac artery segment (TASC B,
C, or D lesions).10 An iliac artery segment was defined as
either the common or external iliac artery. Demographic
data and variables that may have affected patency were
recorded. A stent graft was placed primarily in all lesions.
The kissing balloon technique was used in bilateral proxi-
mal common iliac disease. Iliac occlusions were dilated with
3 to 4 mm diameter balloons to enable passage of the stent
graft. No occlusions were thrombolysed before placement
of the stent graft. Self-expanding stent grafts (Wallgraft,
Boston Scientific, Boston, Mass; Viabahn, W. L. Gore,
Flagstaff, Ariz) were used. No lesion was treated in an
asymptomatic leg. Patients with arteriographically signifi-
cant common femoral artery disease underwent concomi-
tant common femoral endarterectomy, which included
endarterectomy of the profunda, and patch angioplasty.
Significant common femoral artery disease was defined as
stenosis greater than 50%. Heparinization was used during
the procedure to maintain activated clotting time at 300
seconds. Aspirin was administered after the procedure,
unless another form of anticoagulation was needed because
of a separate indication.
Technical success was defined as systolic unenhanced
pressure gradient less than 10 mm Hg across the treated
iliac system after intervention. Assessment of hemodynamic
success was evaluated, according to Society for Vascular
Surgery and American Association for Vascular Surgery
(SVS/AAVS) reporting standards, as increase in corre-
sponding lower extremity ankle-brachial index (ABI) of at
least 0.1.18 Clinical success was determined with the Amer-
ican Hospital Association classification: 3, markedly im-
proved, ABI  .90; 2, improved but continued symp-
toms, ABI increased by .10; 1, minimally better, ABI
increased by  .10; 0, no change; 1, mildly worse; 2,
one category worse, ie, claudication to rest pain; 3, un-
expected major amputation.19
Assessment of aortoiliac patency was determined with
SVS/AAVS criteria. Follow-up included physical examina-
tion, segmental pulse volume recordings, and ABI deter-
mination at 1 month and every 6 months thereafter. Pa-
tients without symptoms with normal femoral pulse were
determined to have patent intervention. Patients with re-
current symptoms, diminished femoral pulse, or ABI de-
creased more than 0.15 underwent duplex ultrasound scan-
ning or angiography. Stenosis greater than 50%,
unenhanced gradient more than 10 mm Hg, or peak sys-
tolic velocity ratio more than two and a half times was
considered evidence of recurrent disease. Primary patency
was defined as a patent artery without recurrent stenosis or
further endovascular intervention. Secondary patency was
defined as a patent artery that required repeat endovascular
intervention because of recurrent stenosis. Endovascular
failure was defined as necessity for a surgical inflow proce-
dure, either axillobifemoral bypass grafting or femorofemo-
ral crossover bypass grafting, to maintain iliac artery pa-
tency. Repeat endovascular intervention was performed at
the discretion of the attending surgeon, but usually recur-
rent unilateral iliac system occlusion or multisegment dis-
ease involving all four iliac segments was treated with
surgical revascularization.
Statistical analysis was performed with a microcomput-
er-based statistical program (Statview; Abacus Concepts,
Fig 2. Primary and secondary stent-graft patency of iliac artery
segments in all patients.
Fig 3. Primary stent-graft patency of iliac artery segments in
patients without common femoral endarterectomy versus patients
with concomitant common femoral endarterectomy. P  .21
between groups, log-rank test.
Table 1. Independent predictors of primary patency after
stent-graft placement to treat multisegment iliac occlusive
disease
Variable Success Failure P*
CFA endarterectomy 59 20 .16
Mean stent diameter (mm) 9.1 8.1 .15
Post stent angioplasty (mm) 7.6 7.2 .31
Female gender (%) 38 40 .43
CFA, Common femoral artery.
*Univariate analysis.
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Berkeley, Calif). Patency rates were calculated with the
Kaplan-Meier life table method, and statistical difference
between survival curves was determined with the Mantel-
Cox log-rank test. P  .05 was considered significant.
Numerical data are expressed as mean  SEM.
RESULTS
During the study 34 patients underwent stent grafting
of at least two distinct iliac artery segments or a completely
occluded or stenotic single segment. No patients were lost
to follow-up. Indication for treatment was rest pain in 65%
of patients and tissue loss in 35% of patients. Sixty-two
percent of patients were men; mean patient age was 63 2
years (range, 40 to 101 years). Twenty-six percent of
patients had diabetes; 71% had significant coronary artery
disease, 71% had hyperlipidemia, 21% had renal insuffi-
ciency (serum creatinine concentration2.0 mg/dL), and
71% were recent or active tobacco users.
The 34 patients underwent placement of 76 stent grafts
for treatment of disease in 59 segments of iliac artery.
Self-expanding stent grafts were used, Wallgraft in 88% of
procedures and Viabahn in 12% of procedures. One seg-
ment was treated in 38% of patients (all external iliac
lesions, 41% external iliac occlusion), two segments were
treated in 50% of patients, three segments were treated in
6% of patients, and all four segments were treated in 6% of
patients. Fifteen percent of patients had TASC B iliac
lesions, 44% had TASC C iliac lesions, and 41% had TASC
D iliac lesions. Mean length of iliac lesion treated was 13.7
 .8 cm. Seventy-four percent of lesions required predila-
tion with a balloon (mean and median diameter, 3 mm;
range, 3-6 mm). Mean stent-graft diameter was 9 mm
(range, 7-12 mm). Post-dilation mean balloon diameter
was 8 mm (range, 5-9 mm). Fifty-three percent of patients
underwent concomitant common femoral endarterectomy
with patch angioplasty, because of angiographically evident
common femoral artery disease with stenosis 50%. In
patients who underwent percutaneous placement of stent
grafts, the 9F or 10F sheath was closed with two percuta-
neous suture closure devices (Perclose, Redwood City,
Calif).
Technical success was achieved in 100% of cases. The
overall complication rate was 3%, with 30-day mortality rate
of 3%. The single death during that period was not attrib-
utable to endovascular intervention, but to complications
from metastatic lung cancer. One patient required buttock
fasciotomy, more than likely due to embolization after stent
grafting of a total external iliac occlusion in which the
occlusion was predilated with a 6 mm balloon. Forty- seven
percent of patients underwent percutaneous procedures;
the remainder underwent open procedures because of sig-
nificant common femoral artery disease. Open procedures
included common femoral artery and profunda endarterec-
tomy with patch angioplasty, after which the stent graft was
placed. Mean length of stay for all patients was 1 hospital
day.
Initial hemodynamic success was achieved in 100% of
cases. Mean preintervention ABI was .30  .03, which
increased to .59 .04 post-intervention. Clinical improve-
ment, according to AHA classification, was demonstrated
in 97% of patients: 3 in 53% of patients, 2 in 35%, and
1 in 12%. No major amputations were required in this
patient population.
During follow up of 21 months, an additional endovas-
cular intervention or surgical inflow procedure was re-
quired in 12% of patients to maintain iliac patency. In those
four patients the procedure failed because of distal external
iliac artery or proximal common femoral artery disease,
which required subsequent common femoral endarterec-
tomy and either external iliac artery stent grafting or open
surgical inflow procedure. Three of four endovascular fail-
ures occurred in patients who did not undergo concomi-
tant common femoral endarterectomy at the initial stent-
graft placement. Mean time to repeat intervention was 11
 1 months.
At life table analysis, 12% of patients had died during
the study. Primary aortoiliac patency and secondary pa-
tency of all treated arteries are shown in Fig 2. At 6 and 12
months after intervention, primary patency rates for the
aortoiliac segment was 87% and 70%, respectively, and
secondary patency rates were 88% and 88%, respectively.
Primary patency with and without common femoral
endarterectomy are shown in Fig 3. There was a trend
toward improved primary iliac artery patency in patients
who underwent concomitant common femoral endarterec-
tomy compared with patients who did not undergo this
procedure, but the difference was not significant, likely
because of small sample size. At 6 and 12 months the
primary patency rate in patients who underwent concomi-
tant common femoral endarterectomy was 94% and 94%,
respectively, compared with 79% and 53% in patients who
did not undergo common femoral endarterectomy.
Univariate analysis of procedural variables is shown in
the Table. We did not identify any variables that were
predictors of primary patency failure. We did note a trend
toward better primary patency rates in patients who under-
went concomitant common femoral endarterectomy and in
patients who received grafts with larger diameter.
DISCUSSION
We investigated whether endovascular technique, spe-
cifically, stent grafting, is durable in treatment of multiseg-
ment iliac artery occlusive disease. Our study patients had
diffuse iliac disease, with TASC B, C, or D lesions. At 12
months, secondary graft patency rate in all patients was
88%. Only 12% of patients required repeat intervention,
and morbidity and mortality were only 3%. Mean ABI
increased from .30 to .59 in this group of patients, with
associated clinical improvement in 97% of patients. The
relatively modest increase in ABI is indicative of the high
prevalence of associated infrainguinal disease in this cohort
of patients, all of whom had limb-threatening leg ischemia.
Many patients had significant comorbid conditions that
would have precluded aortobifemoral bypass grafting.
These results were improved from those of our previous
study of stent treatment in a similar group of patients with
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diffuse iliac disease, in which 42% of patients required
repeat intervention and 16% of those patients required
multiple interventions.7 The primary patency rate in the
present study is also markedly improved from that in our
previous study of patients with multisegment iliac disease,
in which the primary patency rate at 12 months was 47%,
compared with 70% in the present study.7
We, and others, have reported that presence of external
iliac disease is a powerful predictor of decreased primary
and primary assisted iliac patency rates.5-8,20 Other re-
ported predictors of worse outcome after iliac artery angio-
plasty are female sex,20,21 renal insufficiency, and critical
ischemia.4 In the present study we did not identify predic-
tors of primary patency failure with univariate or multivar-
iate analysis. We did note that patients who underwent
concomitant common femoral endarterectomy and re-
ceived stent grafts with larger diameter had better primary
patency rates. With accrual of more patients these variables
may become significant.
There are few reports in the literature that concentrate
on endovascular treatment of multisegment iliac occlusive
disease, and even fewer reports of treatment of these lesions
with stent grafting. Murphy et al22 treated 94 complex iliac
artery lesions, with primary patency rates of 78% at 1 year
and 53% at 2 years. Primary assisted patency rates were 86%
at 1 year and 82% at 2 years. Mean lesion length in their
study was 6.5 cm, compared with 13.8 cm in the present
study. Use of stent grafts to treat diffuse iliac occlusive
disease was reported by Cynamon et al9 and Nevelsteen et
al.23 Cynamon et al9 used homemade stent grafts (6 mm
polytetrafluoroethylene grafts sewn to 294 Palmaz stents).
Eighteen grafts were placed to treat iliac occlusive disease in
17 patients with limb-threatening ischemia and significant
common femoral artery disease. These authors reported a
primary patency rate of 81% at 2 years. Nevelsteen et al23
placed 29 stent grafts in 24 patients to treat claudication (n
 7) or limb-threatening ischemia (n 27). Mean primary
and secondary cumulative patency rates after 1 year were
85% and 95%, respectively. All patients in this series under-
went outflow procedures, ie, profundaplasty or femoral
distal grafting. Krajcer et al24 reported preliminary results
of a comparative study of Wallstents versus Wallgrafts. Ten
patients received 6 Wallgrafts (4 in the left and 2 in the right
iliac artery) and 9 Wallstents (5 in the left and 4 in the right
iliac artery). At 1-month follow-up, marked improvement
was noted in claudication symptoms in 4 of 5 patients who
received the Wallgrafts. In the Wallstent group, symptoms
improved in 1 patient; in another patient, symptoms im-
proved in one limb and worsened in the other limb, and the
remainder of patients demonstrated no symptom improve-
ment. To date, our study includes the largest group of
patients with multisegment iliac occlusive disease treated
with stent grafting.
In the present study, treatment failed in 4 patients
because of distal external iliac artery or proximal common
femoral artery disease, which required subsequent common
femoral endarterectomy and either external iliac artery stent
grafting or surgical inflow procedure. Eighty percent of
primary patency failures were in patients who did not
undergo concomitant common femoral endarterectomy at
the initial stent-graft placement. Twelve-month primary
patency rate in patients who underwent concomitant com-
mon femoral endarterectomy was 94%, versus 53% in pa-
tients who underwent stent grafting only. These results,
however, were not statistically significant. We have re-
ported our experience with combined common femoral
endarterectomy and external iliac stent placement for treat-
ment of combined common femoral artery and external
iliac artery disease.25. While this study demonstrated a
favorable result in patients who underwent a combined
procedure, because the disease process was more isolated,
they should not be compared with results in the present
series. We are presently trying to identify the best method
for quantifying common femoral artery plaque burden, to
determine which patients would benefit from common
femoral endarterectomy during treatment of severe iliac
occlusive disease.
Our results of endovascular treatment of multisegment
iliac disease with stent grafting cannot be directly compared
with those with surgical bypass grafting, because patients
were selected as appropriate candidates. Overall, the results
of stent-graft treatment of diffuse iliac occlusive disease are
somewhat inferior to those with aortobifemoral bypass
grafting, but appear better than those we have previously
reported for angioplasty and selective stent placement to
treat diffuse iliac disease. Patients at prohibitive risk for
aortobifemoral bypass grafting or extraanatomic bypass
grafting would therefore benefit from this technique.
In conclusion, early results of stent-graft placement to
treat diffuse iliac occlusive disease are promising. Concom-
itant common femoral endarterectomy may improve dura-
bility in selected patients.
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